Home › Research › Disease mechanisms
Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons
Megan E. Bosch, Jason D. Ulrich. Molecular Neurodegeneration Advances, 2026-01-27
Topic: Brain proteins, microglia and lab models
Plain-language summary
Primary and secondary tauopathies are major causes of dementia characterized by the abnormal accumulation of microtubule-associated protein tau. Tau aggregation initiates neuronal dysfunction and death, while despite the distinct and pathological features of individual tauopathies, accumulating evidence shows that these disorders converge on shared mechanistic pathways marked by chronic inflammation and progressive neuronal loss. The innate immune response has been extensively studied in this context, yet the contribution of the adaptive immune system, particularly T cells, has only recently gained attention. In this review, we examine emerging evidence for adaptive immune involvement in tauopathies, including mechanisms that drive T cell activation and infiltration into the central nervous system, their effector functions once within the parenchyma, and how these responses interact with innate immune signaling. We also highlight potential therapeutic strategies aimed at modulating adaptive immunity in primary and secondary tauopathies. Current findings suggest that tau accumulation and glial-driven neuroinflammation creates an environment that promotes the activation and recruitment of effector T cells into the tauopathy brain. Importantly, blocking or reshaping the T cell responses shows promise for mitigating neurodegeneration, highlighting the adaptive immune system as a potential therapeutic target.
What this study adds
Evidence grade: Low
This review describes emerging evidence that tau accumulation and glial-driven inflammation promote the activation and recruitment of effector T cells into the tauopathy brain. It suggests that blocking or reshaping T cell responses shows promise for reducing neurodegeneration, but this is a review of early evidence, not a tested treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bosch, M. E., & Ulrich, J. D. (2026). Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons. Molecular Neurodegeneration Advances. https://doi.org/10.1186/s44477-026-00020-5
Vancouver
Bosch ME, Ulrich JD. Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons. Molecular Neurodegeneration Advances. 2026. doi:10.1186/s44477-026-00020-5. PMID: 41695615.
BibTeX
@article{bosch2026-41695615,
author = {Bosch, Megan E. and Ulrich, Jason D.},
title = {{Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons}},
journal = {Molecular Neurodegeneration Advances},
year = {2026},
doi = {10.1186/s44477-026-00020-5},
pmid = {41695615},
url = {https://doi.org/10.1186/s44477-026-00020-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Current findings suggest that tau accumulation and glial-driven neuroinflammation creates an environment that promotes the activation and recruitment of effector T cells into the tauopathy brain.
Why it matters
This review describes emerging evidence that tau accumulation and glial-driven inflammation promote the activation and recruitment of effector T cells into the tauopathy brain. It suggests that blocking or reshaping T cell responses shows promise for reducing neurodegeneration, but this is a review of early evidence, not a tested treatment.
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular Neurodegeneration Advances) |
| Journal's citation record | 0 / 4 | Molecular Neurodegeneration Advances: journal h-index 3 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jason D. Ulrich: h-index 44 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41695615) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s44477-026-00020-5
- PubMed: 41695615
- Original source →
- Free full text: Molecular Neurodegeneration Advances →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.